Genmab As Stock Annual Yield
| GMAB Stock | USD 20.17 0.48 2.32% |
Genmab AS fundamentals help investors to digest information that contributes to Genmab AS's financial success or failures. It also enables traders to predict the movement of Genmab Stock. The fundamental analysis module provides a way to measure Genmab AS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genmab AS stock.
Genmab | Annual Yield |
Genmab AS Company Annual Yield Analysis
Genmab AS's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Genmab Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Genmab AS is extremely important. It helps to project a fair market value of Genmab Stock properly, considering its historical fundamentals such as Annual Yield. Since Genmab AS's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Genmab AS's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Genmab AS's interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
| Competition |
In accordance with the recently published financial statements, Genmab AS has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio File Import Now
Portfolio File ImportQuickly import all of your third-party portfolios from your local drive in csv format |
| All Next | Launch Module |
Genmab AS ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Genmab AS's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Genmab AS's managers, analysts, and investors.Environmental | Governance | Social |
Genmab Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 10.98 B | ||||
| Shares Outstanding | 635.24 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 8.41 % | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | 66.53 X | ||||
| Price To Book | 2.86 X | ||||
| Price To Sales | 0.69 X | ||||
| Revenue | 16.47 B | ||||
| Gross Profit | 14.6 B | ||||
| EBITDA | 5.56 B | ||||
| Net Income | 5.64 B | ||||
| Cash And Equivalents | 21.61 B | ||||
| Cash Per Share | 33.05 X | ||||
| Total Debt | 770 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 13.11 X | ||||
| Book Value Per Share | 502.60 X | ||||
| Cash Flow From Operations | 7.38 B | ||||
| Short Ratio | 1.39 X | ||||
| Earnings Per Share | 1.02 X | ||||
| Price To Earnings To Growth | 0.70 X | ||||
| Target Price | 36.56 | ||||
| Number Of Employees | 2.63 K | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 13.67 B | ||||
| Total Asset | 35.29 B | ||||
| Retained Earnings | 19.02 B | ||||
| Working Capital | 30.66 B | ||||
| Current Asset | 12.65 B | ||||
| Current Liabilities | 823.51 M | ||||
| Net Asset | 35.29 B |
About Genmab AS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Genmab AS Piotroski F Score and Genmab AS Altman Z Score analysis. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.38) | Earnings Share 1.02 | Revenue Per Share 30.6997 | Quarterly Revenue Growth 0.176 | Return On Assets 0.1095 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.